The Microbiome In Vivo Gene Editing System ecosystem spans upstream suppliers of reagents, midstream technology developers and system integrators, and downstream distributors and end‑users that generate research or therapeutic data. Upstream participants deliver enzymes, vectors, and culture media that define performance limits. Midstream actors combine these inputs into integrated editing platforms, provide bioinformatics tools, and assemble turnkey kits for laboratory or clinical deployment. Downstream channels handle regulatory clearance, logistics, and user training, ultimately delivering edited microbiome models or therapeutic candidates to academic, biotech, and pharmaceutical R&D programs. Value is created through the conversion of raw biological components into validated editing systems and captured by each tier via product margins, service contracts, and data licensing. Midstream collaborations with academic consortia also accelerate protocol standardization, reinforcing the value chain.